The Cancer Informatics Shared Resource exists to provide infrastructure and expertise that enable Cancer Center members and activities to adopt and deploy good information practices. These low-profile but crucial resources serve to integrate and responsibly curate Cancer Center information throughout the enterprise. Data integrity, consistency, comparability, and interoperability are thereby enhanced. Data-dependent activities and services throughout the Cancer Center are rendered more efficient and reliable as a consequence. The Resource is divided into four teams and an administrative unit. The four teams are: 1) The Cancer Database and Registry (CDR) Team which provides data design, data harvesting, and data integration of all pertinent cancer information for all cancer patients within the Mayo enterprise. The CDR resource serves as the heart of Cancer Center informatics operations, services, data design, and integration. It serves by design as the core for study and disease-specific database extensions. 2) The Study and Disease Databases Team was created to exploit our investment in the CDR and fashion database extensions atop the core database, without duplicating core content. This team also engages in the design and deployment of data access methods relevant to cancer investigators that are latent in the Mayo-IBM Life Sciences Warehouse project, a major partnership between Mayo and IBM which intends to systematically harvest, organize, and responsibly deliver patient data - from genotype to phenotype. 3) The Bioinformatics Team has been assembled from multiple resources to assist Mayo cancer investigators in the use of bioinformatics tools to pinpoint the genetic roots of cancer. Services include the installation and maintenance of genomic analysis software and their associated databases on shared hardware platforms that locally support the computationally intensive requirements of the Cancer Center. And 4) the Informatics Infrastructure Team comprises a multidisciplinary cadre of investigators who contribute importantly to achieving clinical and genomic data that are comparable, interoperable, and consistent. Examples of such infrastructure services include the integration and support of standard terminologies and data structures, the invocation of Metadata for query and data navigation, and the normalization of clinical data harvested from multiple clinical domains and physical locations into comparable and consistent data elements.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA015083-32
Application #
7253324
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2006-03-01
Budget End
2007-02-28
Support Year
32
Fiscal Year
2006
Total Cost
$1
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Kurmi, Kiran; Hitosugi, Sadae; Yu, Jia et al. (2018) Tyrosine Phosphorylation of Mitochondrial Creatine Kinase 1 Enhances a Druggable Tumor Energy Shuttle Pathway. Cell Metab 28:833-847.e8
O'Mara, Tracy A; Glubb, Dylan M; Amant, Frederic et al. (2018) Identification of nine new susceptibility loci for endometrial cancer. Nat Commun 9:3166
Wallace, Sumer K; Halverson, Jessica W; Jankowski, Christopher J et al. (2018) Optimizing Blood Transfusion Practices Through Bundled Intervention Implementation in Patients With Gynecologic Cancer Undergoing Laparotomy. Obstet Gynecol 131:891-898
Shrestha, Shikshya; Zhang, Cheng; Jerde, Calvin R et al. (2018) Gene-Specific Variant Classifier (DPYD-Varifier) to Identify Deleterious Alleles of Dihydropyrimidine Dehydrogenase. Clin Pharmacol Ther 104:709-718
Hu, G; Dasari, S; Asmann, Y W et al. (2018) Targetable fusions of the FRK tyrosine kinase in ALK-negative anaplastic large cell lymphoma. Leukemia 32:565-569
Geller, James I; Fox, Elizabeth; Turpin, Brian K et al. (2018) A study of axitinib, a VEGF receptor tyrosine kinase inhibitor, in children and adolescents with recurrent or refractory solid tumors: A Children's Oncology Group phase 1 and pilot consortium trial (ADVL1315). Cancer 124:4548-4555
Luchtel, Rebecca A; Dasari, Surendra; Oishi, Naoki et al. (2018) Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements. Blood 132:1386-1398
Oishi, Naoki; Brody, Garry S; Ketterling, Rhett P et al. (2018) Genetic subtyping of breast implant-associated anaplastic large cell lymphoma. Blood 132:544-547
DuBois, Steven G; Mosse, Yael P; Fox, Elizabeth et al. (2018) Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma. Clin Cancer Res 24:6142-6149
Farber, Benjamin A; Lalazar, Gadi; Simon, Elana P et al. (2018) Non coding RNA analysis in fibrolamellar hepatocellular carcinoma. Oncotarget 9:10211-10227

Showing the most recent 10 out of 1129 publications